Physician profile
Mark P Spurlock
NPI 1548208374
$3,276.70
in general payments reported to CMS, 2019-2025
10 companies · $277 in 2025
The $277 reported for 2025 was more than what 86% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $334 · 2021: $162 · 2022: $402 · 2023: $744 · 2024: $643 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,380.31 | 2019-2024 | Epic, Navitor |
| Atricure, INC. | $569.10 | 2020-2025 | Atricure Cryoice Cryoablation System (Cryo2), Synergy Ablation System, Atriclip Laa Exclusion System |
| Intuitive Surgical, INC. | $470.07 | 2019 | |
| Boston Scientific Corporation | $213.23 | 2022-2024 | Watchman Access System |
| Abiomed | $207.26 | 2021-2025 | Impella |
| Angiodynamics, INC. | $149.15 | 2022 | |
| Edwards Lifesciences Corporation | $144.44 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pinnacle Biologics, INC | $84.19 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $42.30 | 2025 | Exparel |
| Janssen Pharmaceuticals, INC | $16.65 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Spurlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.